Hibernation and Congestive Heart Failure

Overview

Journal Heart Fail Rev

Date 2003 May 27

PMID 12766496

Citations 2

Authors

David P Dutka

Paolo G Camici

Affiliations

Soon will be listed here.

Abstract

The most common cause of heart failure is coronary artery disease, and whilst intensive treatment of acute coronary syndromes and myocardial infarction continue to reduce the mortality associated with these conditions, many survivors develop heart failure. In general, heart failure secondary to ischaemic heart disease results from: (i) irreversible myocyte loss due to infarction with scar formation; (ii) chronic left ventricular dysfunction which may recover after revascularisation (hibernating myocardium); (iii) changes in remote myocardium (adverse remodelling). A number of studies suggest that patients with post-ischaemic heart failure may derive symptomatic and prognostic benefit from coronary revascularisation and most of this benefit is thought to derive from functional improvement of hibernating myocardium. Although the mechanisms of hibernation remain poorly understood, studies with positron emission tomography have shown that blood flow to hibernating myocardium is usually within or only slightly below the normal range whilst the coronary vasodilator reserve is always severely reduced and the concept that stunning and hibernation may be causally related has gained support in recent years. There is increasing consensus amongst clinicians regarding the importance of identifying and treating hibernating myocardium in patients with coronary artery disease and heart failure, and a randomised study comparing optimum medical treatment to optimum medical treatment with complete revascularisation has just commenced in the United Kingdom (HEART-UK) and will provide guidance regarding diagnosis and treatment of these patients.

Citing Articles

The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention.

Fang H, Fang Y, Chen Y, Sheu J, Lee W Cardiol Res Pract. 2023; 2023:9226722.

PMID: 36896424 PMC: 9991473. DOI: 10.1155/2023/9226722.

Impaired myocardial oxidative metabolism in the remote normal region in patients in the chronic phase of myocardial infarction and left ventricular remodeling.

Ohte N, Narita H, Iida A, Wakami K, Asada K, Fukuta H J Nucl Cardiol. 2009; 16(1):73-81.

PMID: 19152131 DOI: 10.1007/s12350-008-9006-4.

References

Ambrosio G, Betocchi S, Pace L, Losi M, Perrone-Filardi P, Soricelli A . Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease. Circulation. 1996; 94(10):2455-64. DOI: 10.1161/01.cir.94.10.2455. View

Barnes E, Baker C, Dutka D, Rimoldi O, Rinaldi C, Nihoyannopoulos P . Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia. Heart. 2000; 83(3):283-9. PMC: 1729349. DOI: 10.1136/heart.83.3.283. View

Alderman E, Fisher L, Litwin P, Kaiser G, Myers W, Maynard C . Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983; 68(4):785-95. DOI: 10.1161/01.cir.68.4.785. View

Cleland J . Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J. 1999; 19 Suppl P:P32-9. View

Rees G, Bristow J, Kremkau E, Green G, Herr R, Griswold H . Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med. 1971; 284(20):1116-20. DOI: 10.1056/NEJM197105202842002. View

Camici P, Dutka D . Repetitive stunning, hibernation, and heart failure: contribution of PET to establishing a link. Am J Physiol Heart Circ Physiol. 2001; 280(3):H929-36. DOI: 10.1152/ajpheart.2001.280.3.H929. View

Marinho N, Keogh B, Costa D, Lammerstma A, Ell P, Camici P . Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation. 1996; 93(4):737-44. DOI: 10.1161/01.cir.93.4.737. View

McMurray J, Petrie M, Murdoch D, Davie A . Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1999; 19 Suppl P:P9-16. View

Camici P, Wijns W, Borgers M, De Silva R, Ferrari R, Knuuti J . Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation. 1997; 96(9):3205-14. DOI: 10.1161/01.cir.96.9.3205. View

10.

Camici P, Ferrannini E, Opie L . Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis. 1989; 32(3):217-38. DOI: 10.1016/0033-0620(89)90027-3. View

11.

Sun K, Czernin J, Krivokapich J, Lau Y, Bottcher M, Maurer G . Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium. Circulation. 1996; 94(12):3146-54. DOI: 10.1161/01.cir.94.12.3146. View

12.

Sambuceti G, Parodi O, Marcassa C, Neglia D, Salvadori P, Giorgetti A . Alteration in regulation of myocardial blood flow in one-vessel coronary artery disease determined by positron emission tomography. Am J Cardiol. 1993; 72(7):538-43. DOI: 10.1016/0002-9149(93)90348-g. View

13.

Pagano D, Bonser R, Townend J, Ordoubadi F, Lorenzoni R, Camici P . Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart. 1998; 79(3):281-8. PMC: 1728621. DOI: 10.1136/hrt.79.3.281. View

14.

Rahimtoola S . A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985; 72(6 Pt 2):V123-35. View

15.

Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki L, Ruotsalainen U . Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996; 93(9):1658-66. DOI: 10.1161/01.cir.93.9.1658. View

16.

Eitzman D, Kanter H, Vom Dahl J, Kirsh M, Deeb G, Schwaiger M . Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992; 20(3):559-65. DOI: 10.1016/0735-1097(92)90008-b. View

17.

Heyndrickx G, Millard R, McRitchie R, Maroko P, Vatner S . Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975; 56(4):978-85. PMC: 301954. DOI: 10.1172/JCI108178. View

18.

Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55. DOI: 10.1056/NEJM199605233342101. View

19.

Dreyfus G, Duboc D, Blasco A, Vigoni F, Dubois C, Brodaty D . Myocardial viability assessment in ischemic cardiomyopathy: benefits of coronary revascularization. Ann Thorac Surg. 1994; 57(6):1402-7; discussion 1407-8. DOI: 10.1016/0003-4975(94)90091-4. View

20.

Di Carli M, Asgarzadie F, Schelbert H, Brunken R, Laks H, Phelps M . Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995; 92(12):3436-44. DOI: 10.1161/01.cir.92.12.3436. View